Consegna Pharma

Consegna Pharma is a private, pre-revenue biotech developing long-acting injectable formulations of off-patent drugs using its Computational Drug Delivery™ platform. Its lead program, CP216, is a long-acting naloxone designed to prevent renarcotization in opioid overdose reversal, addressing a critical limitation of current short-acting antidotes. The company utilizes the FDA's 505(b)(2) regulatory pathway to potentially accelerate development and reduce risk. Its business model appears focused on out-licensing its formulated product portfolio to larger pharmaceutical partners for commercialization.

Computational Drug Delivery™, an AI-based software platform (ADSR™) that calculates formulation specifications for long-acting injectables using data on the drug, excipients, desired release profile, and physiological environment. It aims to accelerate development and reduce clinical and manufacturing scale-up risk.

Competition in opioid overdose reversal includes existing naloxone products (e.g., Narcan, Kloxxado) and other entities potentially developing longer-acting antagonists. In the broader LAI space, Consegna competes with established drug delivery companies and generic pharmaceutical firms with formulation expertise, though its AI-driven platform aims to provide a speed and efficiency advantage.